Apoptosis induced by chemotherapeutic agents involves c-Jun N-terminal kinase activation in sarcoma cells lines

Journal of Orthopaedic Research

Volumn 24, Issue 6, 2006, Pages 1153-1162

  Koyama, Takaaki ^a,b   Mikami, Takashi ^a,b   Koyama, Takashi ^b   Imakiire, Atsuhiro ^b   Yamamoto, Kengo ^b   Toyota, Hiroko ^a   Mizuguchi, Junichiro ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis; c Jun N terminal kinase (JNK); Cis diaminedichloroplatinum (CDDP); Doxorubicin (DXR); Sarcoma cells

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ENZYME ANTIBODY; JANUS KINASE 1; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME INDUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; ISOENZYMES; MITOGEN-ACTIVATED PROTEIN KINASE 8; SARCOMA;

EID: 33745026288     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20176     Document Type: Article

References (40)

1. Bramwell VH. 2000. Osteosarcomas and other cancers of bone. Curr Opin Oncol 12:330-336.
2. Colvin OM. 1997. Drug resistance in the treatment of sarcomas. Semin Oncol 24:580-591.
3. Eilber FR, Rosen G. 1989. Adjuvant chemotherapy for osteosarcoma. Semin Oncol 16:312-322.
4. Kartalou M, Essigmann JM. 2001. Mechanisms of resistance to cisplatin. Mutat Res 478:23-43.
5. Reed JC. 1999. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11:68-75.
6. Herr I, Debatin KM. 2001. Cellular stress response and apoptosis in cancer therapy. Blood 98:2603-2614.
7. Lei K, Nimnual A, Zong WX, et al. 2002. The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol 22:4929-4942.
8. Scorrano L, Korsmeyer SJ. 2003. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 304:437-444.
9. Chang L, Karin M. 2001. Mammalian MAP kinase signalling cascades. Nature 410:37-40.
10. Johnson GL, Lapadat R. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912.
11. Weston CR, Davis RJ. 2002. The JNK signal transduction pathway. Curr Opin Genet Dev 12:14-21.
12. Chen YR, Wang X, Templeton D, et al. 1996. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 271:31929-31936.
13. Levresse V, Marek L, Blumberg D, et al. 2002. Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells. Mol Pharmacol 62:689-697.
14. Mansouri A, Ridgway LD, Korapati AL, et al. 2003. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278:19245-19256.
15. Minden A, Karin M. 1997. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1333:F85-F104.
16. Lamb JA, Ventura JJ, Hess P, et al. 2003. JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell 11:1479-1489.
17. Potapova O, Basu S, Mercola D, et al. 2001. Protective role for c-Jun in the cellular response to DNA damage. J Biol Chem 276:28546-28553.
18. Tournier C, Hess P, Yang DD, et al. 2000. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288:870-874.
19. Sanchez-Perez I, Murguia JR, Perona R. 1998. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16:533-540.
20. Potapova O, Haghighi A, Bost F, et al. 1997. The Jun kinase/ stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 272:14041-14044.
21. Hotta T, Suzuki H, Nagai S, et al. 2003. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J Orthopaed Res 21:949-957.
22. Takata R, Fukasawa S, Hara T, et al. 2004. Cerivastatin-induced apoptosis of human aortic smooth muscle cells through partial inhibition of basal activation of extracellular signal-regulated kinases. Cardiovasc Pathol 13: 41-48.
23. Takada E, Toyota H, Suzuki J, et al. 2001. Prevention of anti-IgM-induced apoptosis accompanying G1 arrest in B lymphoma cells overexpressing dominant-negative mutant form of c-Jun N-terminal kinase 1. J Immunol 166:1641-1649.
24. Han SY, Kim SH, Heasley LE. 2002. Differential gene regulation by specific gain-of-function JNK1 proteins expressed in Swiss 3T3 fibroblasts. J Biol Chem 277: 47167-47174.
25. Toyota H, Yanase N, Yoshimoto T, et al. 2003. Calpain-induced Bax-cleavage product is a more potent inducer of apoptotic cell death than wild-type Bax. Cancer Lett 189:221-230.
26. Shaulian E, Karin M. 2002. AP-1 as a regulator of cell life and death. Nat Cell Biol 4:E131-E136.
27. Herault O, Colombat P, Domenech J, et al. 1999. A rapid single-laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population. Br J Haematol 104:530-537.
28. DeAngelis LM. 2003. Benefits of adjuvant chemotherapy in high-grade gliomas. Semin Oncol 30:15-18.
29. Shannon C, Smith I. 2003. Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 45:77-90.
30. Boulikas T, Vougiouka M. 2003. Cisplatin and platinum drugs at the molecular level [review]. Oncol Rep 10:1663-1682.
31. Kim J, Freeman MR. 2003. JNK/SAPK mediates doxorubicin-induced differentiation and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 79:321-328.
32. Davison K, Mann KK, Waxman S, et al. 2004. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103:3496-3502.
33. Hayakawa J, Depatie C, Ohmichi M, et al. 2003. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem 278:20582-20592.
34. Zanke BW, Boudreau K, Rubie E, et al. 1996. The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr Biol 6:606-613.
35. Bain J, McLauchlan H, Elliott M, et al. 2003. The specificities of protein kinase inhibitors: an update. Biochem J 371:199-204.
36. Krilleke D, Ucur E, Pulte D, et al. 2003. Inhibition of JNK signaling diminishes early but not late cellular stress-induced apoptosis. Int J Cancer 107:520-527.
37. Takada E, Toyota H, Furuhata M, et al. 2002. Requirement of c-Jun N terminal kinase and P38 mitogen-activated protein kinase for anti-IgM-induced reduction in mitochondrial membrane potential in CH31 B lymphoma cells. Immunol Lett 81:93-98.
38. Lei K, Davis RJ. 2003. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 100:2432-2437.
39. Fuchs SY, Adler V, Pincus MR, et al. 1998. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 95:10541-10546.
40. Chandar N, Billig B, McMaster J, et al. 1992. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 65:208-214.